LMP1 activates both the canonical and non-canonical pathways of NFκB signaling [14,63–65], and inhibition of NFκB blocked the survival of LMP1 transgenic lymphocytes and LMP1-positive and -negative lymphoma cells. Here, PDLIM7 is linked to lymphoma.